### Pyruvate Kinase Deficiency

**Abstract:** 1679

**Title:** Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency


**Acceptance Status:** Poster

**Session Title:** 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

**Abstract:** 2583

**Title:** Baseline Characteristics of Patients in Peak: A Global, Longitudinal Registry of Patients with Pyruvate Kinase Deficiency

**Authors:** Grace RF, Boscoe AN, Bowden C, Glader B, Kanno H, Layton DM, van Beers E, Vives Corrons J-L, Yan Y, Bianchi P

**Acceptance Status:** Poster

**Session Title:** 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III

### MITAPIVAT (AG-348)

**Abstract:** 2600

**Title:** Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Thalassemia: Interim Results from an Ongoing, Phase 2, Open-Label, Multicenter Study

**Authors:** Kuo KHM, Layton DM, Li A, Al-Samkari H, Tai F, Lynch M, Uhlig K, Vichinsky EP

**Acceptance Status:** Poster

**Session Title:** 112. Thalassemia and Globin Gene Regulation: Poster III

### ENASIDENIB (AG-221)

**Abstract:** 2402

**Title:** A Phase I Study of the IDH2 Inhibitor Enasidenib as Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation


**Acceptance Status:** Poster

**Session Title:** 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster II

**Presentation is supported but not sponsored by Agios.**

### Pyruvate Kinase Deficiency

**Abstract:** 1679

**Title:** Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency


**Acceptance Status:** Poster

**Session Title:** 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

**Abstract:** 2583

**Title:** Baseline Characteristics of Patients in Peak: A Global, Longitudinal Registry of Patients with Pyruvate Kinase Deficiency

**Authors:** Grace RF, Boscoe AN, Bowden C, Glader B, Kanno H, Layton DM, van Beers E, Vives Corrons J-L, Yan Y, Bianchi P

**Acceptance Status:** Poster

**Session Title:** 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III

**Abstract:** 2600

**Title:** Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Thalassemia: Interim Results from an Ongoing, Phase 2, Open-Label, Multicenter Study

**Authors:** Kuo KHM, Layton DM, Li A, Al-Samkari H, Tai F, Lynch M, Uhlig K, Vichinsky EP

**Acceptance Status:** Poster

**Session Title:** 112. Thalassemia and Globin Gene Regulation: Poster III

**Abstract:** 681

**Title:** Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease


**Acceptance Status:** Oral Presentation

**Session Title:** 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Novel Treatments for Sickle Cell Disease

**Presentation is supported but not sponsored by Agios.**

**Abstract:** 84

**Title:** The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis


**Acceptance Status:** Oral Presentation

**Session Title:** 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron

**Presentation is supported but not sponsored by Agios.**

All presentations will be available on the Virtual Congress platform from the time and date of their scheduled presentation.

**Presentations will be accessible for ~30 days after the congress ends.**

© 2020 Agios Pharmaceuticals, Inc. All rights reserved.

**IDH-ALL-0034 10/2020**